沙美特罗丙酸氟替卡松治疗慢性阻塞性肺病临床分析

Clinical Analysis of Salmeterol and Fluticasone Propionate in Treatment of Preeclampsia

目的分析慢性阻塞性肺病患者采用沙美特罗丙酸氟替卡松治疗的临床效果。方法方便选取该院2015年6月—2017年5月收治的102例COPD患者根据随机抽签法分为治疗组(51例,常规药物治疗基础上采用沙美特罗丙酸氟替卡松治疗)和对照组(51例,采用常规药物治疗),对比两组患者治疗效果、治疗前后1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1/预计值%)以及用力呼气量占用力肺活量比值(FEV1/FVC%)等肺功能指标变化、不良反应发生率等情况。结果治疗组治疗总有效率98.0%显著高于对照组82.4%(χ~2=6.035 2,P<0.05),两组患者治疗后FEV1、FEV1/预计值、FEV1/FVC等肺功能指标相对于治疗前均有所升高(P<0.05),但治疗组患者治疗后各项肺功能指标水平更高于对照组(P<0.05)。治疗组患者出现头痛、震颤、心悸等不良反应发生率5.9%显著低于对照组17.6%(χ~2=5.923,P<0.05)。结论 COPD患者采用沙美特罗丙酸氟替卡松治疗的临床效果较为理想,可有效改善患者肺功能,且不良反应较轻,值得在临床上广泛推广。

Objective To analyze the clinical effect of salmeterol and propionate in treatment of preeclampsia.Methods 102 cases of COPD patients admitted and treated in our hospital from June 1,2015 to May 31,2017 were convenient selected and randomly divided into two groups with 51 cases in each,the control group used the routine drugs,while the treatment group used the salmeterol and propionate on the basis of the routine drugs,and the treatment effect,FEV1,and FEV1/predicative value%)and FEV1/FVC%and incidence rate of adverse reactions were compared between the two groups.Results The total treatment effective rate in the treatment group was obviously higher than that in the control group(98.0%vs 82.4%)(χ2=6.035 2,P<0.05),and the FEV1,and FEV1/predicative value)and FEV1/FVC after treatment of the two groups increased compared with those before treatment(P<0.05),but after treatment,the levels of various indicators in the treatment group were higher than those in the control group(P<0.05),and the incidence rate of adverse reactions such as headache,tremor,palpitation in the treatment group was obviously lower than that in the control group(5.9%vs 17.6%)(χ2=5.92 3,P<0.05).Conclusion The clinical effect of salmeterol and propionate in treatment of preeclampsia is ideal,which can effectively improve the lung function with mild adverse reactions,which is worth wide promotion in clinic.